Carmen Wong, MD
Family Medicine · Houston, TXNPI 1356347512
Payments from drug & device makers
Across 542 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$946
- GSK$905
- Boehringer Ingelheim$763
- AbbVie$661
- Bayer$509
- plus $4K from 31 others
What the payments were for
- Food & beverage$9,10298%
- Education$1191%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 93 | $1,992 |
| Novo Nordisk | 69 | $946 |
| GSK | 57 | $905 |
| Boehringer Ingelheim | 41 | $763 |
| AbbVie(2 entities) | 46 | $661 |
| Bayer | 32 | $509 |
| Integra Lifesciences Corporation | 7 | $423 |
| Amgen(2 entities) | 21 | $362 |
| Lilly USA, LLC | 18 | $347 |
| Amarin Pharma, Inc. | 26 | $242 |
| Esperion Therapeutics, Inc. | 14 | $236 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $225 |
| Merck | 17 | $187 |
| Pfizer | 19 | $174 |
| Hikma Pharmaceuticals USA | 8 | $158 |
| Teva Pharmaceuticals USA, Inc. | 10 | $153 |
| Sunovion Pharmaceuticals Inc. | 7 | $128 |
| Johnson & Johnson | 6 | $106 |
| Mannkind Corporation | 3 | $97 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Mimedx Group, Inc. | 1 | $84 |
| Exact Sciences | 3 | $63 |
| Astellas Pharma US Inc | 2 | $48 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| Seqirus USA Inc | 2 | $40 |
| Novartis | 2 | $40 |
| Eisai Inc. | 2 | $38 |
| Genentech USA, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Almatica Pharma LLC | 1 | $28 |
| Mylan Specialty L.p. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Surgenex LLC | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| RGH Enterprises LLC | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRIMATRIX$230
- AIRSUPRA$219
- FARXIGA$219
- BREZTRI$219
- INTEGRA MESHED BILAYER WOUND MATRIX$130
- INTEGRA WOUND MATRIX (IWM)$130
- INTEGRA DERMAL REGENERATION TEMPLATE$130
- INTEGRA FLOWABLE WOUND MATRIX$130
- OMNIGRAFT$100
- MEDIHONEY$100
- TCC-EZ$100
- AMNIOEXCEL$100
How this compares
$9,280 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $58,105 |
| JardianceEmpagliflozin | 35 | $41,173 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $34,700 |
| EliquisApixaban | 31 | $31,116 |
| FarxigaDapagliflozin Propanediol | 22 | $22,361 |
| TrulicityDulaglutide | 12 | $13,651 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $13,236 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $11,808 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $5,901 |
| Rosuvastatin Calcium | 102 | $3,876 |
| Atorvastatin Calcium | 226 | $3,782 |
| Gabapentin | 107 | $3,560 |
| Nifedipine ErNifedipine | 87 | $3,091 |
| Losartan Potassium | 125 | $2,551 |
| Levothyroxine Sodium | 230 | $2,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $946 | $58,10535 claims |
| Boehringer IngelheimJardiance | $763 | $41,17335 claims |
| GSKTrelegy Ellipta | $905 | $34,70029 claims |
| PfizerEliquis | $174 | $31,11631 claims |
| AstraZenecaFarxiga | $1,992 | $22,36122 claims |
| Lilly USA, LLCTrulicity | $347 | $13,65112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.